[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA117845C2 - Композиція стійкого аерозольного розчину під тиском комбінації глікопіронію броміду та формотеролу - Google Patents

Композиція стійкого аерозольного розчину під тиском комбінації глікопіронію броміду та формотеролу

Info

Publication number
UA117845C2
UA117845C2 UAA201606910A UAA201606910A UA117845C2 UA 117845 C2 UA117845 C2 UA 117845C2 UA A201606910 A UAA201606910 A UA A201606910A UA A201606910 A UAA201606910 A UA A201606910A UA 117845 C2 UA117845 C2 UA 117845C2
Authority
UA
Ukraine
Prior art keywords
solution composition
glycopyrronium bromide
aerosol solution
hydroxy
salt
Prior art date
Application number
UAA201606910A
Other languages
English (en)
Inventor
Сауро Бонеллі
Діеґо Копеллі
Албері Массіміліано Дальї
Франческа Усберті
Енріко Дзамбеллі
Original Assignee
К'Єзі Фармачеутічі С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117845(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by К'Єзі Фармачеутічі С.П.А. filed Critical К'Єзі Фармачеутічі С.П.А.
Publication of UA117845C2 publication Critical patent/UA117845C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007—Mechanical counters
    • A61M15/0071—Mechanical counters having a display or indicator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A61M2039/226—Spindles or actuating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0238—General characteristics of the apparatus characterised by a particular materials the material being a coating or protective layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується композиції аерозольного розчину, яку призначено для застосування з дозуючим інгалятором під тиском та яка містить глікопіронію бромід та формотерол або його сіль або сольват зазначеної солі, вибірково, у комбінації з одним або кількома додатковими активними інгредієнтами, стабілізованими вибраною кількістю неорганічної кислоти, та в якій кількість продукту деградації N-(3-бром)-[2-гідрокси-5-[1-гідрокси-2-[1-(4-метоксифеніл)пропан-2-іламіно]етил]феніл]формаміду знаходиться нижче межі кількісного аналізу у разі її зберігання впродовж принаймні 6 місяців в умовах прискореної деградації з температурою 25 °C та з 60 % відносною вологістю (RH) у контейнері з внутрішнім гумовим покриттям, що містить кополімер тетрафторетилену та гексафторпропілену (FEP). Одним або кількома активними інгредієнтами цієї композиції можуть бути інгаляційні кортикостероїди, вибрані з беклометазону дипропіонату, будесоніду або його 22R-епімеру, цеклезоніду, флунізоліду, флутиказону пропіонату, флутиказону фуроату, мометазону фуроату тощо.
UAA201606910A 2013-12-30 2014-12-23 Композиція стійкого аерозольного розчину під тиском комбінації глікопіронію броміду та формотеролу UA117845C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199784 2013-12-30
PCT/EP2014/079259 WO2015101576A1 (en) 2013-12-30 2014-12-23 Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Publications (1)

Publication Number Publication Date
UA117845C2 true UA117845C2 (uk) 2018-10-10

Family

ID=49886777

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201606910A UA117845C2 (uk) 2013-12-30 2014-12-23 Композиція стійкого аерозольного розчину під тиском комбінації глікопіронію броміду та формотеролу

Country Status (34)

Country Link
US (2) US10596113B2 (uk)
EP (3) EP3089735B1 (uk)
JP (2) JP6563950B2 (uk)
KR (2) KR101861119B1 (uk)
CN (2) CN105848641B (uk)
AR (1) AR098982A1 (uk)
AU (1) AU2014375301B2 (uk)
BR (1) BR112016014583B1 (uk)
CA (1) CA2935305C (uk)
CL (1) CL2016001653A1 (uk)
CY (1) CY1120668T1 (uk)
DK (1) DK3089735T3 (uk)
EA (1) EA033227B1 (uk)
ES (1) ES2687345T3 (uk)
HK (1) HK1225313A1 (uk)
HR (1) HRP20181551T1 (uk)
HU (1) HUE039513T2 (uk)
IL (1) IL246498B (uk)
LT (1) LT3089735T (uk)
MA (1) MA39155A1 (uk)
MX (1) MX368835B (uk)
MY (1) MY182861A (uk)
PE (1) PE20160997A1 (uk)
PH (1) PH12016501268B1 (uk)
PL (1) PL3089735T3 (uk)
PT (1) PT3089735T (uk)
RS (1) RS57687B1 (uk)
SA (1) SA516371427B1 (uk)
SG (1) SG11201605311UA (uk)
SI (1) SI3089735T1 (uk)
TN (1) TN2016000261A1 (uk)
TW (1) TWI660747B (uk)
UA (1) UA117845C2 (uk)
WO (1) WO2015101576A1 (uk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5914354B2 (ja) 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
ES2464520T3 (es) 2009-12-23 2014-06-03 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
RU2561052C2 (ru) * 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
LT3089735T (lt) * 2013-12-30 2018-09-10 Chiesi Farmaceutici S.P.A. Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija
MY176191A (en) * 2013-12-30 2020-07-24 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
BR112018011266B1 (pt) 2015-12-04 2023-11-21 Mexichem Fluor S.A. De C.V. Composição farmacêutica, recipiente vedado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CA3037092C (en) * 2016-09-19 2022-06-21 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
WO2020084549A1 (en) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Nebulization composition comprising glycopyrrolate and formoterol
WO2021009572A1 (en) * 2019-07-12 2021-01-21 Kindeva Drug Delivery L.P. Aerosol formulation, canister and inhaler containing the formulation, and method of use
WO2021110239A1 (en) 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
WO2021151857A1 (en) 2020-01-28 2021-08-05 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
GB2593970B (en) 2020-02-20 2024-09-04 Chiesi Farm Spa Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CA3186956A1 (en) 2020-07-31 2022-02-03 Chemo Research , S.L. Combination therapy for inhalation administration
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
CN116419749A (zh) 2020-10-09 2023-07-11 奇斯药制品公司 用于加压定量吸入器的药物制剂
CN118475343A (zh) * 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023227782A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
NZ509489A (en) 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
EP1241113A1 (en) * 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
RU2438660C2 (ru) 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
NZ548300A (en) 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
CN100457087C (zh) * 2004-02-27 2009-02-04 奇斯药制品公司 用于加压计量吸入器的稳定的药用溶液制剂
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
CA2565747A1 (en) * 2004-05-13 2005-12-01 Chiesi Farmaceutici S.P.A. Medicinal aerosol formulation products with improved chemical stability
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1879620A2 (en) 2005-03-30 2008-01-23 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2201934A1 (en) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
RU2561052C2 (ru) 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
ES2464520T3 (es) * 2009-12-23 2014-06-03 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
JP5914354B2 (ja) * 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
ES2467928T3 (es) 2009-12-23 2014-06-13 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
EP2613828B1 (en) 2010-09-06 2019-11-27 CHIESI FARMACEUTICI S.p.A. Metered-dose inhaler actuator, metered-dose inhaler
BR112013029507A2 (pt) * 2011-05-17 2019-09-24 Pearl Therapeutics Inc método para tratar uma doença ou um distúrbio
BR112015002757A2 (pt) 2012-08-29 2017-07-04 Chiesi Farm Spa acionador para dispositivo inalador de aerossol, objeto em forma cilíndrica oca, inalador, acionador de inalador dosimétrico, kit e uso de um acionador
LT3089735T (lt) * 2013-12-30 2018-09-10 Chiesi Farmaceutici S.P.A. Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija
MY176191A (en) * 2013-12-30 2020-07-24 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Also Published As

Publication number Publication date
JP2017507169A (ja) 2017-03-16
JP6823118B2 (ja) 2021-01-27
JP2019206557A (ja) 2019-12-05
DK3089735T3 (en) 2018-09-17
US20150182450A1 (en) 2015-07-02
CN111150728A (zh) 2020-05-15
TN2016000261A1 (en) 2017-10-06
MX2016008594A (es) 2016-09-26
PH12016501268A1 (en) 2016-08-15
NZ721642A (en) 2021-02-26
MX368835B (es) 2019-10-18
US10617638B2 (en) 2020-04-14
US10596113B2 (en) 2020-03-24
WO2015101576A1 (en) 2015-07-09
IL246498B (en) 2020-05-31
EP3089735A1 (en) 2016-11-09
US20160303045A1 (en) 2016-10-20
MA39155A1 (fr) 2017-04-28
CL2016001653A1 (es) 2017-08-25
EP3089735B1 (en) 2018-07-11
LT3089735T (lt) 2018-09-10
KR101861117B1 (ko) 2018-05-28
CN105848641B (zh) 2021-07-09
HK1225313A1 (zh) 2017-09-08
PH12016501268B1 (en) 2016-08-15
PL3089735T3 (pl) 2018-12-31
SA516371427B1 (ar) 2018-12-24
TWI660747B (zh) 2019-06-01
MY182861A (en) 2021-02-05
HUE039513T2 (hu) 2019-01-28
RS57687B1 (sr) 2018-11-30
CN105848641A (zh) 2016-08-10
CA2935305A1 (en) 2015-07-09
PT3089735T (pt) 2018-10-19
TW201609185A (zh) 2016-03-16
JP6563950B2 (ja) 2019-08-21
EA201691126A1 (ru) 2016-12-30
AR098982A1 (es) 2016-06-22
HRP20181551T1 (hr) 2018-11-30
EA033227B1 (ru) 2019-09-30
KR20160104041A (ko) 2016-09-02
IL246498A0 (en) 2016-08-31
PE20160997A1 (es) 2016-10-14
EP3566694A1 (en) 2019-11-13
KR20180032660A (ko) 2018-03-30
BR112016014583A2 (uk) 2017-08-08
KR101861119B1 (ko) 2018-05-28
SI3089735T1 (sl) 2018-10-30
BR112016014583B1 (pt) 2022-12-20
AU2014375301A1 (en) 2016-07-14
CN111150728B (zh) 2024-02-06
EP3384898A1 (en) 2018-10-10
SG11201605311UA (en) 2016-07-28
ES2687345T3 (es) 2018-10-24
AU2014375301B2 (en) 2020-03-26
CY1120668T1 (el) 2019-12-11
CA2935305C (en) 2022-07-12

Similar Documents

Publication Publication Date Title
PH12016501268A1 (en) Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
MY176191A (en) Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
AR081540A1 (es) Proceso para proveer particulas con cargas electroestaticas reducidas
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
RU2012142295A (ru) Способ приготовления частиц носителя для сухих порошков для ингаляции
NZ600789A (en) Aerosol formulation for copd
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
JP2014527056A5 (uk)
JO3024B1 (ar) صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات
CO2022012207A2 (es) Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada
TH171992A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
TH171993A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
RU2021104054A (ru) Ингалятор отмеренных доз с распылением сжатым воздухом, содержащий забуференный фармацевтический состав
PL432374A1 (pl) Nowy inhalacyjny system terapeutyczny dostarczający zredukowaną ilość propionianu flutikazonu i salmeterolu o zwiększonej skuteczności i profilu bezpieczeństwa
RU2021101525A (ru) Ингалятор отмеренных доз с распылением сжатым воздухом, содержащий забуференный фармацевтический состав
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero
TH171992B (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล